Tag Archives: Dietmar Berger

Sanofi Ceases Development of Tusamitamab Ravtansine for NSCLC after Trial Misses Primary Endpoint

(IN BRIEF) Sanofi has announced the discontinuation of the global clinical development program for tusamitamab ravtansine, following an interim analysis of the Phase 3 CARMEN-LC03 trial. The trial assessed tusamitamab ravtansine as a monotherapy in previously treated metastatic non-squamous non-small … Read the full press release

Sarclisa Combination Treatment Shows Promise in Phase 3 Trial for Newly Diagnosed Multiple Myeloma Patients

(IN BRIEF) The Phase 3 IMROZ trial, assessing the use of Sarclisa® (isatuximab) in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd), has achieved its primary efficacy endpoint at a planned interim analysis. The trial demonstrated a statistically significant improvement … Read the full press release